Showing 1 posts of 1 posts found.


UK biotech Pulmocide secures $30m for inhalable lung disease therapies

March 20, 2017
Research and Development, Sales and Marketing pulmocide, pulmonary aspergillosis, respiratory syncytial virus

Pulmocide, a UK biotech run by a former GlaxoSmithKline scientists and based in London, has secured $30.4 million in Series …

Latest content